1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials
  4. >>Diversity & Inclusion

Clinical Trial Diversity Measures Primed For Inclusion In US FDA User Fee Legislation

 
• By Sue Sutter

House subcommittee hears testimony on merits of various proposals to increase diversity of clinical trial participants; whether lawmakers ultimately favor measures that impose enforceable obligations on sponsors, or merely incentivize more diverse enrollment, remains to be seen.

Game tokens
FDA user fee legislation is likely to include measures aimed at promoting more diversity in study enrollment. • Source: Alamy

US lawmakers showed strong support for attaching to Food and Drug Administration user fee legislation provisions aimed at increasing the diversity of clinical trials, but whether those measures will impose enforceable obligations on sponsors, or merely incentivize more diverse enrollment, remains to be seen.

Four of the 22 bills discussed at a House Energy and Commerce Committee/Health Subcommittee legislative hearing on 17 March relate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diversity & Inclusion

More from Clinical Trials

Cell/Gene Therapy Cost Recovery Options Could Include Pre-Approval Public ‘Bridge’ Funding

 
• By Kate Rawson

Expanded funding for cost recovery could dovetail with FDA Commissioner Martin Makary’s idea for a “conditional approval” pathway based on a plausible mechanism of action.

UK MHRA: Bacteriophage Developers Wanted ‘More Clarity’ On UK Framework

 
• By Eliza Slawther

Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.

MHRA Backs Bacteriophage Innovation To Fight Antimicrobial Resistance

 
• By Eliza Slawther

The UK regulator wants to help companies to develop bacteriophages for the treatment of infections. Its first guidance on this topic offers advice to researchers and sets out the regulatory requirements they will need to meet.